EGFR and non-small cell lung carcinoma: The DTCs from EGFR‐mutant NSCLC have been shown to be resistant to the treatment by osimertinib and gefitinib via the promotion of the expression of MCL1, an antiapoptotic protein, through mTORC1‐induced mRNA translational regulation at the posttranscriptional level.137